Mode
Text Size
Log in / Sign up

Multidrug-Resistant Tuberculosis

Part of Tuberculosis

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Multidrug-Resistant Tuberculosis

12 trials tracked for Multidrug-Resistant Tuberculosis: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 585 citations.

12Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 3 Phase 2 8
  1. Phase 3 Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Completed · 585 cited
  2. Phase 3 Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis Completed · 170 cited
  3. Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Completed · 61 cited
  4. Phase 4 Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients Completed
  5. Phase 2 Treatment Shortening of MDR-TB Using Existing and New Drugs Completed
  6. Phase 2 Linezolid to Treat Extensively-Drug Resistant Tuberculosis Completed
Show 6 more trials
  1. Phase 2 A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB) Completed
  2. Phase 2 Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB Completed
  3. Phase 2 A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 Completed
  4. Phase 2 Linezolid Dosing Strategies in Drug-Resistant TB Completed
  5. Phase 2 A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) Completed
  6. Phase 2 A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Multidrug-Resistant Tuberculosis: what the trials found

Pretomanid has demonstrated significant efficacy in achieving culture-negative status by 8 weeks (p<0.001) 5. Clinical outcomes for Pretomanid also showed low rates of bacteriologic failure, relapse, or clinical failure at both 26 weeks and 78 weeks post-treatment across various study arms 3. Additionally, a trial evaluating Pretomanid reported positive changes in total sperm count from baseline at 12 and 44 weeks 7.

Delamanid showed significant results in sputum culture conversion (SCC) rates using both MGIT systems and solid culture media compared to other regimens (p=0.0083; p=0.0021) 9. In a large-scale trial, the addition of Delamanid to OBR did not show a statistically significant difference in time to SCC or proportions of patients achieving SCC at 2, 6, 18, 24, or 30 months (p=0.0562; p=0.3818; p=0.5945) 4. Delamanid was associated with high rates of treatment responders using both MGIT and solid culture media (approximately 75-82%) 10. Pharmacokinetic data for Delamanid established an absorption rate constant (Ka) of 0.254 and an absorption lag time (ALAG1) of 1.38 11.

Other interventions included the addition of different doses of clarithromycin 2.

Recent results — preliminary, needs further review

  • Linezolid (600 mg) showed no statistically significant difference in time to 26 weeks stable culture conversion (p=0.0546) or in the proportion of participants discontinuing treatment due to adverse events (p=0.58) or specifically for Linezolid (p=0.82) 1.

For the clinician treating this condition

  • Pretomanid is associated with rapid achievement of culture-negative status within 8 weeks and low rates of clinical failure at long-term follow-up.
  • Delamanid demonstrates significant sputum culture conversion rates and high responder rates across multiple study designs.
  • Linezolid (600 mg) showed no statistically significant difference in time to stable culture conversion or discontinuation rates compared to its comparator.

AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Tuberculosis

Related studies from across the Tuberculosis family.

Meta-analysis-guided sampling plan targets 14 zoonotic and animal diseases across India
Neurology Meta-analysis
Meta-analysis-guided sampling plan targets 14 zoonotic and animal diseases across India New sampling plan helps track diseases jumping from animals to humans
This meta-analysis pools prevalence estimates for 10 zoonotic and 4 transboundary animal diseases in India, reporting a range of 4 to 30% ac…
A new plan for monitoring animal diseases in India helps track infections like Q-fever and scrub typhus before they spread to people.
Multi-scale computational methods identify pivotal tuberculosis vulnerabilities and predict drug resistance with high fidelity
Drug Pipeline Sys. Review
Multi-scale computational methods identify pivotal tuberculosis vulnerabilities and predict drug resistance with high fidelity Computational Methods Identify New Targets for Tuberculosis Treatment
This systematic review evaluates multi-scale computational methods including machine learning and molecular dynamics for tuberculosis drug d…
New computer modeling techniques are identifying key targets and predicting drug resistance to help speed up the development of tuberculosis…
Host-directed therapy including metformin and statins may modulate immune response in tuberculosis patients
Allergy & Immunology Sys. Review
Host-directed therapy including metformin and statins may modulate immune response in tuberculosis patients Repurposed Drugs Like Metformin May Help Fight Tuberculosis
This narrative review explores host-directed therapy (HDT) as an adjunctive strategy to modulate immune responses and limit immunopathology …
New research explores how host-directed therapies, including common drugs like metformin and statins, could help the body fight tuberculosis…
3HP with SMS reminders increases treatment completion to 84.9% compared to 65.4% for 4RIF
Infectious Disease RCT
3HP with SMS reminders increases treatment completion to 84.9% compared to 65.4% for 4RIF SMS reminders help more people finish tuberculosis treatment
This randomized controlled trial of 210 individuals with tuberculosis infection found that 3HP with SMS reminders resulted in a higher treat…
A new trial shows that a shorter treatment plan paired with text message reminders helps more people finish their tuberculosis medication.
Tobacco smoking history increases odds of antibiotic-resistant infections including tuberculosis-related resistance
Infectious Disease Meta-analysis
Tobacco smoking history increases odds of antibiotic-resistant infections including tuberculosis-related resistance Tobacco smoking increases risk of antibiotic-resistant bacterial infections
This meta-analysis of more than 35,000 participants indicates that tobacco smoking history is associated with higher odds of antibiotic-resi…
A large review of over 35,000 people shows that a history of smoking significantly increases the risk of developing drug-resistant infection…
Pre-XDR-TB affects 3% and XDR-TB 1% of MDR-TB patients in Ethiopia
Infectious Disease Meta-analysis
Pre-XDR-TB affects 3% and XDR-TB 1% of MDR-TB patients in Ethiopia Drug-Resistant TB Strains Affect 4% of Ethiopian MDR-TB Patients
This meta-analysis estimates the prevalence of pre-extensively drug-resistant (Pre-XDR-TB) and extensively drug-resistant tuberculosis (XDR-…
About 4 in 100 MDR-TB patients in Ethiopia also carry harder-to-treat TB strains, a new analysis finds.
Gestational HIV exposure does not increase tuberculosis disease risk in children who are HIV-exposed uninfected
Infectious Disease Meta-analysis
Gestational HIV exposure does not increase tuberculosis disease risk in children who are HIV-exposed uninfected Comparing Tuberculosis Risk in Children Exposed to HIV During Pregnancy
This meta-analysis of 18 studies evaluated tuberculosis risk in children who are HIV-exposed uninfected (cHEU) compared to HIV-unexposed uni…
New data shows that children exposed to HIV before birth have similar tuberculosis risks as children never exposed.
Community health workers support infectious disease management and PrEP navigation in agricultural communities
Neurology Sys. Review
Community health workers support infectious disease management and PrEP navigation in agricultural communities Community health workers help farm workers manage infectious diseases
This mini-review examines the role of community health workers (CHWs) in managing infectious diseases among California agricultural workers.…
Community health workers can help farm workers manage serious infections like HIV, tuberculosis, and hepatitis through direct outreach and n…
Short course regimens 3HP, 4HR, and 4R show higher adherence and lower active cases than 9H
Pediatrics Sys. Review
Short course regimens 3HP, 4HR, and 4R show higher adherence and lower active cases than 9H Short Treatment Courses May Reduce Tuberculosis Cases in Children
This network meta-analysis evaluates treatment regimens for children and adolescents with TB infection. The study finds that 4HR reduces act…
New analysis suggests shorter drug regimens for children with tuberculosis may improve treatment completion and reduce the number of active …
Mtb antigen-induced IP-10 shows pooled sensitivity 0.81 and specificity 0.88 for latent TB
Allergy & Immunology Meta-analysis
Mtb antigen-induced IP-10 shows pooled sensitivity 0.81 and specificity 0.88 for latent TB New Blood Test Marker Shows Promise for Detecting Hidden Tuberculosis Infections
This meta-analysis of 24 studies (2,014 participants) evaluated Mycobacterium tuberculosis antigen-induced interferon-gamma-inducible protei…
A new protein marker in the blood helps doctors identify people with hidden tuberculosis infections more accurately.
Comprehensive pulmonary rehabilitation may improve exercise capacity and quality of life in post-tuberculosis lung disease
Neurology Sys. Review
Comprehensive pulmonary rehabilitation may improve exercise capacity and quality of life in post-tuberculosis lung disease Comprehensive Pulmonary Rehabilitation May Improve Life After Tuberculosis
This narrative review examines the role of comprehensive pulmonary rehabilitation for individuals with post-tuberculosis lung disease. The a…
Comprehensive pulmonary rehabilitation programs may improve exercise capacity and quality of life for people living with lung disease after …
Fluoroquinolone resistance acquired more frequently during TB treatment than other anti-TB drugs
Infectious Disease Meta-analysis
Fluoroquinolone resistance acquired more frequently during TB treatment than other anti-TB drugs Bacteria develop resistance to fluoroquinolones more often during tuberculosis treatment
This meta-analysis analyzed 5882 high-quality genomes from 1044 patients to identify MTBC mutations during infection and treatment. It found…
New data shows that tuberculosis bacteria develop resistance to fluoroquinolones more frequently than any other drug during treatment.